Gradient Investments LLC Reduces Stock Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Gradient Investments LLC cut its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 5.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,003 shares of the company’s stock after selling 1,369 shares during the period. Gradient Investments LLC’s holdings in HealthEquity were worth $2,207,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in HQY. Wasatch Advisors LP lifted its position in shares of HealthEquity by 6.6% in the third quarter. Wasatch Advisors LP now owns 7,758,890 shares of the company’s stock valued at $635,065,000 after acquiring an additional 483,269 shares in the last quarter. State Street Corp lifted its holdings in HealthEquity by 0.8% in the 3rd quarter. State Street Corp now owns 3,131,900 shares of the company’s stock valued at $256,346,000 after purchasing an additional 23,613 shares in the last quarter. Clearbridge Investments LLC boosted its stake in shares of HealthEquity by 1.9% during the 2nd quarter. Clearbridge Investments LLC now owns 2,377,204 shares of the company’s stock worth $204,915,000 after purchasing an additional 43,491 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of HealthEquity by 0.7% during the third quarter. Geode Capital Management LLC now owns 2,078,977 shares of the company’s stock worth $170,197,000 after buying an additional 15,145 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of HealthEquity by 0.7% in the third quarter. Franklin Resources Inc. now owns 1,640,215 shares of the company’s stock valued at $139,369,000 after buying an additional 11,659 shares during the last quarter. 99.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HQY has been the topic of a number of analyst reports. The Goldman Sachs Group began coverage on shares of HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 target price on the stock. Mizuho initiated coverage on HealthEquity in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price objective for the company. Royal Bank of Canada increased their target price on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Bank of America lifted their price target on HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, BTIG Research increased their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $110.71.

HealthEquity Stock Performance

NASDAQ:HQY opened at $106.88 on Friday. HealthEquity, Inc. has a twelve month low of $65.01 and a twelve month high of $107.87. The firm has a market capitalization of $9.26 billion, a price-to-earnings ratio of 98.06, a PEG ratio of 1.86 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.51. The firm’s fifty day simple moving average is $99.60 and its 200 day simple moving average is $87.39.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Monday, December 9th. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.12). HealthEquity had a return on equity of 9.70% and a net margin of 8.41%. During the same period in the previous year, the company posted $0.40 earnings per share. As a group, equities research analysts expect that HealthEquity, Inc. will post 2.32 earnings per share for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $101.56, for a total transaction of $837,870.00. Following the completion of the transaction, the director now directly owns 66,469 shares in the company, valued at approximately $6,750,591.64. This represents a 11.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the sale, the director now directly owns 3,784 shares of the company’s stock, valued at $363,642.40. The trade was a 21.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 34,289 shares of company stock valued at $3,355,718 over the last 90 days. 2.20% of the stock is owned by corporate insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.